Modality
Bispecific Ab
MOA
KRASG12Di
Target
Nectin-4
Pathway
PD-1/PD-L1
LGS
Development Pipeline
Preclinical
~Jan 2016
→ ~Apr 2017
Phase 1
Jul 2017
→ Aug 2031
Phase 1Current
NCT03656882
800 pts·LGS
2017-07→2031-08·Completed
800 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-09-186mo agoConference· LGS
2031-08-265.4y awayInterim· LGS
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Complet…
Catalysts
Conference
2025-09-18 · 6mo ago
LGS
Interim
2031-08-26 · 5.4y away
LGS
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03656882 | Phase 1 | LGS | Completed | 800 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| ION-3857 | Ionis | Preclinical | Nectin-4 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα |